PHARVARIS N.V. EO -12 (9EN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-37.95 Million ≈ $-44.37 Million USD) by net assets (€271.27 Million ≈ $317.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PHARVARIS N.V. EO -12 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does PHARVARIS N.V. EO -12 carry for a breakdown of total debt and financial obligations.
PHARVARIS N.V. EO -12 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Encore Capital Group Inc
NASDAQ:ECPG
|
0.017x |
|
Vietnam Export Import Commercial Joint Stock Bank
VN:EIB
|
0.296x |
|
dentalcorp Holdings Ltd
TO:DNTL
|
0.037x |
|
Paradox Interactive AB (publ)
ST:PDX
|
0.205x |
|
Adriatic Metals Plc
AU:ADT
|
-0.451x |
|
Jiangsu Yunyi Electric
SHE:300304
|
0.013x |
|
Alexander & Baldwin Holdings Inc
NYSE:ALEX
|
0.013x |
|
Acadia Healthcare Company Inc
NASDAQ:ACHC
|
0.022x |
Annual Cash Flow Conversion Efficiency for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARVARIS N.V. EO -12 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 9EN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €271.27 Million ≈ $317.15 Million |
€-137.07 Million ≈ $-160.25 Million |
-0.505x | -12.63% |
| 2024-12-31 | €267.76 Million ≈ $313.04 Million |
€-120.13 Million ≈ $-140.44 Million |
-0.449x | -85.17% |
| 2023-12-31 | €384.05 Million ≈ $448.99 Million |
€-93.05 Million ≈ $-108.78 Million |
-0.242x | +46.16% |
| 2022-12-31 | €149.26 Million ≈ $174.50 Million |
€-67.16 Million ≈ $-78.52 Million |
-0.450x | -106.78% |
| 2021-12-31 | €204.95 Million ≈ $239.61 Million |
€-44.60 Million ≈ $-52.14 Million |
-0.218x | -- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more